Clinical Trials · NCT06077864
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 5,531
- Start date
- Nov 2023
- Locations
- 540 sites, 35 countries
- Primary endpoint
- Time to first occurrence of any of the adjudicated components of the composite endpoint consisting of: CV death, non-fatal stroke, non-fatal MI, ischaemia related coronary revascularisation, or HFE (to demonstrate non-inferiority)